Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers

In brief

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults. This study is intended to provide data in support of further clinical development of the RSV+HMPV vaccine candidate. The study will consist of 4 cohorts and 11 vaccine groups (RSV+HMPV \[6 dose levels\], placebo and 4 control groups). The duration of the study will be approximately 12 months for each participant.

Key facts

Study ID

NCT07734649

Run by

Sanofi

People needed

2400

Starts

2026-07-22

Expected to finish

2028-05-03

Last updated by the study team

2026-07-29

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 60 years or older on the day of inclusion
• Non-childbearing potential (ie, post-menopausal for at least 1 year or surgically sterile)

You may not qualify if…

• History of laboratory-confirmed RSV and/or laboratory-confirmed HMPV infection affecting the participant and/or the participant's household in the previous 12 months
• Previous history of myocarditis, pericarditis, and/or myopericarditis
• Screening electrocardiogram (ECG) that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
• Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
• Previous history of Guillain-Barré Syndrome
• Any vaccine given 4 weeks before or 4 weeks after study intervention
• Previous vaccination against RSV and/or HMPV with an investigational or marketed vaccine
• Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration
• Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months
• Any screening laboratory parameter with laboratory abnormality > Grade 1 or deemed clinically significant by the investigator; if deemed appropriate, investigator may repeat these assessments
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Hawthorne Health - Gadsden City Pharmacy- Site Number : 8400025 — Gadsden, Alabama, United States (enrolling)
• Scottsdale Clinical Trials- Site Number : 8400011 — Scottsdale, Arizona, United States (enrolling)
• Long Beach Research Institute- Site Number : 8400005 — Long Beach, California, United States (enrolling)
• Alliance Clinical - San Diego- Site Number : 8400033 — San Diego, California, United States (enrolling)
• Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400064 — DeLand, Florida, United States (enrolling)
• Accel Research Sites - NeuroStudies- Site Number : 8400063 — Decatur, Georgia, United States (enrolling)
• DM Clinical Research - Chicago- Site Number : 8400050 — Melrose Park, Illinois, United States (enrolling)
• DM Clinical Research - Detroit- Site Number : 8400049 — Southfield, Michigan, United States (enrolling)
• Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400016 — Lincoln, Nebraska, United States (enrolling)
• Alliance Clinical - Las Vegas- Site Number : 8400034 — Las Vegas, Nevada, United States (enrolling)
• Hawthorne Health - Staten Island- Site Number : 8400026 — Staten Island, New York, United States (enrolling)
• DM Clinical Research - Philadelphia- Site Number : 8400046 — Philadelphia, Pennsylvania, United States (enrolling)
• Coastal Carolina Research Center - North Charleston- Site Number : 8400061 — North Charleston, South Carolina, United States (enrolling)
• Velocity Clinical Research - Austin- Site Number : 8400013 — Austin, Texas, United States (enrolling)
• DM Clinical Research - Sugar Land- Site Number : 8400048 — Sugar Land, Texas, United States (enrolling)
• DM Clinical Research - Tomball- Site Number : 8400045 — Tomball, Texas, United States (enrolling)
• Charlottesville Medical Research- Site Number : 8400062 — Charlottesville, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.